1) Alonso K., Pontiggia P., Sabato A. et al: Systemic hyperthermia in the treatment of HIV related disseminated Kaposi's Sanrcoma. Long term follow-up of patients treated wityh low flow extracorporeal perfusional hyperthermia. Am. J. Clin. Oncol ., 17: 353, 1994

2) Di Filippo F., Carlini S., Cavaliere F., Giannarelli D., Cavallero L. et al: The role of hyperthermic perfusion in the treatment of tumors of the extremities. In: “Consensus on hyperthermia for the 1990's”. Adv. Exp. Med . And Biol . Vol 267, Plenum Press 1990

3) Leveen H., Wapnicks G., Piccone V.A., Falk G. and Ahmed N.: Tumor eradication by radiofrequency thermotherapy. Jama , 235, 2198, 1976

4) Streffer C.: Metabolic changes during and after hyperthermia. Int. Journal of hyperthermia , 1: 305, 1985

5) Pontiggia P., Mc Laren J., Baronzio G., Freitas I.: The biological response to heat. In: “Consensus on hyperthermia for the 1990's”, Adv. Exp. Med. And Biol . Vol. 267, Plenum Press, 1990.

6) Dahl O.: Mechanisms of thermal enhancement of chemotherapeutic cytotoxicity in hyperthermia and oncology. Urano and Douple Eds. VPS Utrecht, 1994

7) Pontiggia P. Mathè G.: A new mode of cancer cell death induced by hyperthermia and non specific (macrophagic) cancer immunotherapy: lysosomal exocytosis. Biomed . Pharmacother.: 48, 331, 1994

8) Pontiggia P., Barni S. Mathè G., Bertone V. Pontiggia E.: Lysosomal exocytosis induced by hyperthermia: a new model of cancer death II- Effect on peritoneal macrophages. Biomed. Pharmacother . 49, 1995

9) Los G., Van Vugt MJH, Pinedo HM: Response of peritoneal solid tumors after intraperitoneal chemohyperthermia treatment with Cisplatin or Carboplatin. Br. J. Cancer 1994; 69. 235-41

10) Rau B., Wust P., Hohenberger P., Loffel H.M., Below C. et al: Preoperative hyperthermia combined with radiochemotherapy in locally advanced rectal cancer. Annals of Surgery 227, 3, 380-389; 1998

11) Reitbroek R., Schglthuis M, bakker P., Van Dijk J, Postma A. et al: Phase II trial of weekly locoregional hyperthermia and Cispltin in patients with previously irradiated recurrent carcinoma of uterine cervix. Cancer 1997; 79: 935-43

12) Lucchetti F., Burattini S., Ferri P., Papa S., Falcieri E.: Actin involvement in apoptotic chromatin changes of hemopoietic cells undergoing hyperthermia. Apoptosis 2002 ; 7(2): 143-52

13) Wachsberger P., Burd R. Wahl M, Leeper D.B.: Betulinici acid sensitization of low pH adapted human melanoma cells to hyperthermia. Int. J. Hyperthermia 2002; 18 (2): 153-64

14) Hildebrandt B., Wust P., Ahlers O., Dieing A.,Kerner T. et al: The cellular and molecular basis of hyperthermia. Crit. Rev. Oncol. Hematol 2002; 43 (1): 33-56

15) YuguchiT., Saito M., Yokoyama Y, Nagata T. Sakamoto T. Tsukada K.: Combined use of hyperthermia and irradiation cause antiporoliferative activity and cell death to humal esophageal carcinoma cells: mainly cycle examination. Hum. Cell 2002; 15 (1) 33-42

16) Wust P. Hildebrandt B., Sreenivasa G., Rau B. Gellermann J. At al: Hyperthermia in combined treatment of cancer. Lancet Oncol 2002; 3 (8); 487-97

17) Li G.C., Mivechi N. and Weitzel G.: Heat shock proteins, thermotolerance and therir relevance for clinical hyperthermia. Int. J. Hyperthermia 1995; 11, 459-488

18) Field SB, Franconi C, editors. Physics and Technology of Hyperthermia . Boston: Nijhoff, 1987

19) RA Read and JS Bedford. Thermal tolerance Br J Radiol 1980. 53: 920-921

20) Hahn GM, Adwankar MK, Basrur VS, Anderson RL. Survival of cells exposed to anticancer drugs after stress. In: Pardue ML, Feramisco JR, Lindquist S. Stress-Induced Proteins . New York, NY: Liss; 1989. p. 223 233

21) Hiraoka and GM Hahn. Changes in pH and blood flow induced by glucose and their effects on hyperthermia with or without BCNU in RIF-1 tumours Int J Hypertherm 1990. 6: 97-103

22) Morimoto RI, Tissieres A, Georgopoulos C. Stress Proteins in Biology and Medicine. Cold Spring Harbor, New York. 1990.

23) HI Robins, A Hugander, and JD Cohen. Whole body hyperthermia in the treatment of neoplastic disease Radiol Clin North Am 1989. 27: 603-610.

24) TV Samulski, ST Clegg, S Das, J MacFall, and DM Prescott. Application of new technology in clinical hyperthermia Int J Hypertherm 1994. 10: 389-394.

25) JR Oleson, TV Samulski, KA Leopold, ST Clegg, MW Dewhirst, RK Dodge, and SL George. Sensitivity of hyperthermia trial outcomes to temperature and time: implications for thermal goals of treatment Int J Radiat Oncol . Biol Phys 1993. 25: 289-297.

26) DS Kapp and R Cox. Thermal treatment parameters are most predictive of outcome in patients with single tumor nodules per treatment field in recurrent adenocarcinoma of the breast Int J Radiat Oncol Biol Phys 1995. 33: 887-899.

27) J van der Zee, GC van Rhoon, JL Wike-Hooley, NS Faithfull, and HS Reinhold. Whole-body hyperthermia in cancer therapy: a report of a phase I-II study Eur J Cancer Clin Oncol 1983. 19: 1189-1200.

28) M Serin, HS Erkal, and A Cakmak. Radiation therapy, cisplatin and hyperthermia in combination in management of patients with recurrent carcinomas of the head and neck with metastatic cervical lymph nodes Int J Hyperthermia 1999. 15: 371-381.

29) CC Vernon. International Collaborative Hyperthermia Group. Radio therapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials Int J Radiol Oncol Biol Phys 1996. 35: 731-744.

30) J Overgaard, D Gonzalez Gonzalez, MCCM Hulshof, G Arcangeli, O Dahl, O Molls, and SM Bentzen. Randomized trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma Lancet 1995. 345: 540-543.

31) R Valdagni and M Amichetti. Report of long-term follow-up in a randomized trial comparing radiation therapy and radiation therapy plus hyperthermia to metastatic lymph-nodes in Stage IV head and neck patients Int J Radiat Oncol Biol Phys 1994. 28: 163-169.

32) IA Petersen and DS Kapp. Local hyperthermia and radiation therapy in the retreatment of superficially located recurrences in Hodgkin's disease Int J Radiat Oncol Biol Phys 1990. 18: 603-611

33) T Sakamoto, H Katoh, T Shimizu, I Yamashita, S Takemori, K Tazawa, and M Fujimaki. Clinical results of treatment of advanced esophageal carcinoma with hyperthermia in combination with chemoradiotherapy Chest 1997. 112: 1487-1493.

34) LH Hartwell and TA Weinert. Checkpoints: controls that ensure the order of cell cycle events Science 1989. 246: 629-634.

35) DO Morgan. Cyclin-dependent kinases: engines, clocks, and microprocessors Ann Rev Cell Dev Biol 1997. 13: 261-291.

36) G Zugmaier and ME Lippman. Effects of TGF beta on normal and malignant mammary epithelium Ann N Y Acad Sci 1990. 593: 272-275.

37) BJ Druker, HJ Mamon, and TM Roberts. Oncogenes, growth factors, and signal transduction N Engl J Med 1989. 321: 1383-1391.

38) AB Pardee. G1 events and regulation of cell proliferation Science 1989. 246: 603-608.

39) DW Goodrich, NP Wang, YW Qian, EY Lee, and WH Lee. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle Cell 1991. 67: 293-302.

40)S Barni, P Pontiggia, V Bertone, R Vaccarone, MG Siulvotti, E Pontiggia, G Mathè. Hyperthermia-induced cell death by apoptosis in myeloma cells. Biomed Pharmacother 2001; 55: 170-3

41) V Bertone, S Barni, MG Silvotti, I Freitas, G Mathè et al. Hyperthermic effect on the human metastatic liver: a TEM study. Anticancer Res. 1997; 17: 4713-6

42) A Amundson, TG Myers, AJ Fornace, and Jr. Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress Oncogene 1998. 17: 3287-3299

43) JI Fabrikant and J Cherry. The kinetics of cellular proliferation in normal and malignant tissues. V. Analysis of labeling indices and potential tissue doubling times in human tumor cell populations J Surg Oncol 1969. 1: 23-47.

44) K Fukuda, T Iwasaka, and T Hachisuga et al . Immunocytochemical detection of S-phase cells in normal and neoplastic cervical epithelium by anti-BrdU monoclonal antibody Anal Quant Cytol Histol 1990. 12: 135-138.

45) L Teodori, ML Trinca, and W Goehde et al . Cytokinetic investigation of lung tumors using the anti-bromodeoxyuridine (BUdR) monoclonal antibody method: comparison with DNA flow cytometric data Int J Cancer 1990. 45: 995-1001.

46) G Weber. Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture Cancer Res 1983. 43: 3466-3492.

47) R Juliano. Cooperation between soluble factors and integrin-mediated cell anchorage in the control of cell growth and differentiation Bioessays 1996. 18: 911-917.

48) M Hall and G Peters. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer Adv Cancer Res 1996. 68: 67-108.

49) CJ Sherr. Cancer cell cycles Science 1996. 274: 1672-1677.

50) A Kamb. Cyclin-dependent kinase inhibitors and human cancer Curr Top Microbiol Immunol 1998. 227: 139-148

51) DW Goodrich and WH Lee. The molecular genetics of retinoblastoma Cancer Surveys 1990. 9: 529-554

52) C Prives and PA Hall. The p53 pathway J Pathol 1999. 187: 112-126.

53) M Akashi and HP Koeffler. Li-Fraumeni syndrome and the role of the p53 tumor suppressor gene in cancer susceptibility Clin Obstet Gynecol 1998. 41: 172-199

54) N Weidner, PR Carroll, J Flax, W Blumenfeld, and J Folkman. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma Am J Pathol 1993. 143: 401-409.

55) N Weidner, JP Semple, WR Welch, and J Folkman. Tumor angiogenesis and metastasis correlation in invasive breast carcinoma N Engl J Med 1991. 324: 1-8.

56) LR Bernstein and LA Liotta. Molecular mediators of interactions with extracellular matrix components in metastasis and angiogenesis Curr Opin Oncol 1994. 6: 106-113.

57) B Mintz and RA Fleischman. Teratocarcinomas and other neoplasms as developmental defects in gene expression Adv Cancer Res 1981. 34: 211-278.

58) MF Pittenger, AM Mackay, and SC Beck et al . Multilineage potential of adult human mesenchymal stem cells Science 1999. 284: 143-147.

59) JJ WilleJr , PB Maercklein, and RE Scott. Neoplastic transformation and defective control of cell proliferation and differentiation Cancer Res 1982. 42: 5139-5146.

60) DB Rifkin and D Moscatelli. Recent developments in the cell biology of basic fibroblast growth factor J Cell Biol 1989. 109: 1-6.

61) E Rozengurt. Early signals in the mitogenic response Science 1986. 234: 161-166

62) HL Moses, EY Yang, and JA Pietenpol. TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights Cell 1990. 63: 245-247.

63) M Peter and I Herskowitz. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle [comment] Cell 1994. 79: 181-184.

64) CJ Sherr. G1 phase progression: cycling on cue [see comments] Cell 1994. 79: 551-555.

65) JL Bennington. Cellular kinetics of invasive squamous carcinoma of the human cervix Cancer Res 1969. 29: 1082-1088.

66) V Castronovo, M Kusaka, A Chariot, J Gielen, and M Sobel. Homeobox genes: potential candidates for the transcriptional control of the transformed and invasive phenotype Biochem Pharmacol 1994. 47: 137-143

67) A McCormick and J Campisi. Cellular aging and senescence Curr Opin Cell Biol 1991. 3: 230-234.

68) R Singal and GD Ginder. DNA methylation Blood 1999. 93: 4059-4070.

69) AP Feinberg and B Vogelstein. Hypomethylation distinguishes genes of some human cancers from their normal counterparts Nature 1983. 301: 89-92.

70) SE Goelz, B Vogelstein, SR Hamilton, and AP Feinberg. Hypomethylation of DNA from benign and malignant human colon neoplasms Science 1985. 228: 187-190.

71) M Carlsson, TH Totterman, P Matsson, and K Nilsson. Cell cycle progression of B-chronic lymphocytic leukemia cells induced to differentiate by TPA Blood 1988. 71: 415-421

72) Gorstein F, Thor A. Tumor markers in diagnostic pathology. In Clinics in Laboratory Medicine. Edited by F Gorstein, A Thor. Philadelphia: WB Saunders, 1990.

73) M Reiss, C Gamba-Vitalo, and AC Sartorelli. Induction of tumor cell differentiation as a therapeutic approach: preclinical models for hematopoietic and solid neoplasms Cancer Treat Rep 1986. 70: 201-218

74) Waxman S, Rossi GB, Takaku F. The Status of Differentiation Therapy of Cancer. New York: Raven, 1988.

75) M Andreeff, R Stone, and J Michaeli et al . Hexamethylene bisacetamide in myelodyplastic syndrome and acute myelogenous leukemia: A Phase II clinical trial with a differentiation-inducing agent Blood 1992. 80: 2604-2609.

76) TR Breitman, SJ Collins, and BR Keene. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid Blood 1981. 57: 1000-1004.

77) BA Chabner. Biological basis for cancer treatment [comment] Ann Intern Med 1993. 118: 633-637.

78) BD Cheson, DM Jasperse, HG Chun, and MA Friedman. Differentiating agents in the treatment of human malignancies Cancer Treat Rev 1986. 13: 129-145.

79) M Andreeff, S Jiang, and X Zhang et al . Expression of bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retionic acid Leukemia 1999. 13: 1881-1892.

80) WK Hong, SM Lippman, and LM Itri et al . Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck [see comments] N Engl J Med 1990. 323: 795-801.

81) FL MeyskensJr . Coming of age the chemoprevention of cancer [editorial; comment] [see comments] N Engl J Med 1990. 323: 825-827.

82) JD Rowley, JC Aster, and J Sklar. The clinical applications of new DNA diagnostic technology on the management of cancer patients JAMA 1993. 270: 2331-2337.

83) JC Reed. Dysregulation of apoptosis in cancer J Clin Oncol 1999. 17: 2941-2953.

84) MO Hengartner and HR Horvitz. Programmed cell death in Caenorhabditis elegans Curr Opin Genet Dev 1994. 4: 581-586.

85) K Hofmann, P Bucher, and J Tschopp. The CARD domain: a new apoptotic signalling motif Trends Biochem Sci 1997. 22: 155-156.

86) P Li, D Nijhawan, and I Budihardjo et al . Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade Cell 1997. 91: 479-489

87) JJ Chou, H Matsuo, H Duan, and G Wagner. Solution structure of the RAIDD CARD and model for CARD/CARD interaction in caspase-2 and caspase-9 recruitment Cell 1998. 94: 171-180.

88) K Kuida, TF Haydar, and CY Kuan et al . Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking Caspase 9 Cell 1998. 94: 325-337.

89) DW Nicholson and NA Thornberry. Caspases: killer proteases Trends Biochem Sci 1997. 22: 299-306.

90) RV Talanian, C Quinlan, and S Trautz et al . Substrate specificities of caspase family proteases J Biol Chem 1997. 272: 9677-9682.

91) NA Thornberry, TA Rano, and EP Peterson et al . A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis J Biol Chem 1997. 272: 17907-17911.

92) MP Boldin, TM Goncharov, YV Goltsev, and D Wallach. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death Cell 1996. 85: 803-815.

93) M Muzio, AM Chinnaiyan, and FC Kischkel et al . FLICE, a novel FADDl-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex Cell 1996. 85: 817-827.

94) L Faleiro, R Kobayashi, H Fearnhead, and Y Lazebnik. Multiple species of CPP32 and Mch2 are the major active caspases present in apoptotic cells EMBO J 1997. 16: 2271-2281.

95) M MacFarlane, K Cain, XM Sun, ES Alnemri, and GM Cohen. Processing/activation of at least four interleukin-1 beta converting enzyme-like proteases occurs during the execution phase of apoptosis in human monocytic tumor cells J Cell Biol 1997. 37: 469-479.

96) SM Srinivasula, T Fernandes-Alnemri, and J Zangrilli et al . The CED-3/interleukin-1 beta converting enzyme-like homolog Mch6 and the lamin-cleaving enzyme Mch2 alpha are substrates for the apoptotic mediator CPP32 J Biol Chem 1996. 271: 27099-27106.

97) X Liu, CN Kim, J Yang, R Jemmerson, and X Wang. Induction of apoptotic programin cell-free extracts: requirement for dATP and cytochrome c Cell 1996. 86: 147-157.

98) J Yang, X Liu, and K Bhalla et al . Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked [see comments] Science 1997. 275: 1129-1132.

99) DR Green and JC Reed. Mitochondria and apoptosis Science 1998. 281: 1309-1312.

100) DR Green. Apoptotic pathways: the roads to ruin Cell 1998. 94: 695-698.

101) H Sakahira, M Enari, and S Nagata. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis [see comments] Nature 1998. 391: 96-99.

102) N Fujita, A Nagahashi, K Nagashima, S Rokudai, and T Tsuruo. Acceleration of apoptotic cell death after the cleavage of Bcl-XL protein by caspase-3-like proteases Oncogene 1998. 17: 1295-1304.

103) EH Cheng, DG Kirsch, and RJ Clem et al . Conversion of bcl-2 to a Bax-like death effector by caspases Science 1997. 278: 1966-1968.

104) RA MacCorkle, KW Freeman, and DM Spencer. Synthetic activation of caspases: artificial death switches Proc Natl Acad Sci U S A 1998. 95: 3655-3660.

105) RJ Clem and LK Miller. Control of programmed cell death by the baculovirus genes p35 and iap Mol Cell Biol 1994. 14: 5212-5222.

106) N Roy, MS Mahadevan, and M McLean et al . The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy Cell 1995. 80: 167-178.

107) AG Uren, M Pakusch, CJ Hawkins, KL Puls, and DL Vaux. Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor-associated factors PNAS 1996. 93: 4974-4978.

108) HR Stennicke, QL Deveraux, and EW Humke et al . Caspase-9 can be activated without proteolytic processing J Biol Chem 1999. 274: 8359-8362.

109) QL Deveraux, N Roy, and HR Stennicke et al . IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases EMBO J 1998. 17: 2215-2223

110) J Dierlamm, M Baens, and I Wlodarska et al . The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21)p6ssociated with mucosa-associated lymphoid tissue lymphomas Blood 1999. 93: 3601-3609.

111) A Greiner, H Seeberger, C Knorr, P Starostik, and HK Muller-Hermelinck. MALT-type B-cell lymphomas escape the sensoring FAS-mediated apoptosis Blood 1998. 92: 484a.

112) G Ambrosini, C Adida, and DC Altieri. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma Nat Med 1997. 3: 917-921.

113) F Li, G Ambrosini, and EY Chu et al . Control of apoptosis and mitotic spindle checkpoint by survivin Nature 1998. 396: 580-584.

114) I Tamm, Y Wang, E Sausville, DA Scudiero, N Vigna, T Oltersdorf, and JC Reed. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs Cancer Res 1998. 58: 5315-5320.

115) CD Lu, DC Altieri, and N Tanigawa. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas Cancer Res 1998. 58: 1808-1812.

116) H Kawasaki, DC Altieri, and CD Lu et al . Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer Cancer Res 1998. 58: 5071-5074.

117) G Ambrosini, C Adida, G Sirugo, and DC Altieri. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting J Biol Chem 1998. 273: 11177-11182.

118) C Adida, PL Crotty, and J McGrath et al . Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation Am J Pathol 1998. 152: 43-49.

119) CA Smith, T Farrah, and RG Goodwin. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death Cell 1994. 76: 959-962.

120) S Nagata. Apoptosis by death factor Cell 1997. 88: 355-365.

121) M Hahne, D Rimoldi, and M Schroter et al . Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape Science 1996. 274: 1363-1366.

122) S Nagata and P Golstein. The Fas death factor Science 1997. 267: 1449-1456.

123) AM Chinnaiyan, K O'Rourke, M Tewari, and VM Dixit. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis Cell 1995. 81: 505-512.

124) AM Chinnaiyan, CG Tepper, and MF Seldin et al . FADD/MORT1 is a common mediator of CD95 (Fas/APO1) and tumor necrosis factor recreptor-induced apoptosis J Biol Chem 1996. 271: 4961-4965.

125) M Muller, S Wilder, and D Bannasch et al . p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs J Exp Med 1998. 188: 2033-2045.

126) LB Owen-Schaub, W Zhang, and JC Cusack et al . Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression Mol Cell Biol 1995. 15: 3032-3040.

127) J Ogasawara, R Watanabe-Fukunaga, and M Adachi et al . Lethal effect of the anti-fas antibody in mice Nature 1993. 364: 806-809.

128) P Schneider, N Holler, and JL Bodmer et al . Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity J Exp Med 1998. 187: 1205-1213.

129) J Kitson, T Raven, and YP Jiang et al . A death-domain-containing receptor that mediates apoptosis Nature 1996. 384: 372-375.

130) AM Chinnaiyan, K O'Rourke, and GL Yu et al . Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95 Science 1996. 274: 990-992.

131) Y Hitoshi, J Lorens, and SI Kitada et al . Toso, a cell surface, specific regulator of Fas-induced apoptosis in T cells Immunity 1998. 8: 461-471.

132) RW Johnstone, E Cretney, and MJ Smyth. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death Blood 1999. 93: 1075-1085.

133) WD Thomas and P Hersey. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells J Immunol 1998. 161: 2195-2200.

134) V Snell, K Clodi, and S Zhao et al . Activity of TNF-related apoptosis-inducing ligand (TRAIL) in haematological malignancies Br J Cancer 1997. 99: 624.

135) M Andreeff, G Wong, B Koziner, E Espiritu, and B Clarkson. Non B-Non T acute lymphoblastic leukemia (ALL): evidence for complete b cell differentiation of a quiescent subpopulation and their response to induction therapy Proc Am Assoc Cancer Res 1985. 26: 28.

136) MM Keane, SA Ettenberg, MM Nau, EK Russell, and S Lipkowitz. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines Cancer Res 1999. 59: 734-741.

137) P Golstein. Cell death: trail and its receptors Curr Biol 1997. 7: R750-R753.

138) H Walczak, RE Miller, and K Ariail et al . Tumoricidal activity of tumor necrosis factor-related apoptosis- inducing ligand in vivo [see comments] Nat Med 1999. 5: 157-163.

139) L Gibson, SP Holmgreen, and DC Huang et al . Bcl-w, a novel member of the bcl-2 family, promotes cell survival Oncogene 1996. 13: 665-675.

140) E Yang, J Zha, and J Jockel et al . Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death Cell 1995. 80: 285-291.

141)M JJ Hunter, BL Bond, and TG Parslow. Functional dissection of the human Bcl2 protein: sequence requirements for inhibition of apoptosis Mol Cell Biol 1996. 16: 877-883.

142) C Borner, I Martinou, and C Mattmann et al . The protein bcl-2 alpha does not require membrane attachment, but two conserved domains to suppress apoptosis J Cell Biol 1994. 126: 1059-1068.

143) T Ito, X Deng, B Carr, and WS May. Bcl-2 phosphorylation required for anti-apoptosis function J Biol Chem 1997. 272: 11671-11673.

144) MV Blagosklonny, T Schulte, P Nguyen, J Trepel, and LM Neckers. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway Cancer Res 1996. 56: 1851-1854.